Th Consultant Thoracic Surgeon Academic Division of Thoracic Surgery Royal Brompton Hospital London United Kingdom Clinical Reader in Thoracic Surgery National Heart and Lung Institute Imperial College London United Kingdom ID: 787286
Download The PPT/PDF document "Mr Eric Lim MB ChB, MSc (Biostatistics),..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Mr Eric LimMB ChB, MSc (Biostatistics), MD, FRCS (C-Th)Consultant Thoracic SurgeonAcademic Division of Thoracic SurgeryRoyal Brompton Hospital, London, United KingdomClinical Reader in Thoracic SurgeryNational Heart and Lung InstituteImperial College, London, United Kingdom
Lessons Learnt
The demise of thoracic surgery (Part II)
Slide2DisclosuresConsultancy / Advisory BoardStrategen, Abbott Molecular, Glaxo Smith Klein, Pfizer, Norvatis, Covidien, EthiconEducational presentations / speakerRoche, Imedex, Glaxo Smith Klein, Lily, Pfizer, Medela, Boehringer Ingelheim Travel, accommodation and course feesCovidien, MedelaResearch fundingScreenCell®, MeledaOtherFounder of Informative Genomics (blood based molecular diagnostics laboratory)Director of the BUPA Cromwell Lung Cancer Screening ProgrammeChief Investigator for MARS 2 – surgery versus no surgery for mesotheliomaChief Investigator for VIOLET – VATS versus thoracotomy for lung cancer
Slide3The demise of thoracic surgery (Part I)We are witnessing unprecedented acceleration in advances in competing radiotherapy technology backed by:Industry (multi-billion dollar companies) UK government Exponential growthInternational research consortiaRCT evidence of superior survival (Chang et al) in early stage lung cancerTo ensure the survival of our speciality, we need to take on (head to head) clinical trials of surgery versus radiotherapy
Slide4UK thoracic surgery research agendaUK Thoracic Surgery Research Collaborative established in 2010Consortia of research active thoracic surgery centresSet up an infrastructure for grant funded thoracic surgery researchSurgeons experience in trial participationeducation in trial conduct (ability to randomise)Thoracic surgery centres financial supportdedicated thoracic surgery research nurses
Slide5Slide6Slide7Slide8Slide9Slide10Slide11Slide12Screening / eligibility
Slide13Eligible / consent
Slide14Slide15Lessons learntSuccessfully recruiting thoracic surgery trialFriends rather than colleaguesSense of communityResearch facilities, nurses and training support (finance) critical to successSense of fairness is importantNew funding model by number recruitedGroup authorship (VIOLET Trialists - not Lim et al)
Slide16Future directionsVIOLET and MARS 2 (in application stages to HTA) will reinforce funding and resources for thoracic surgery clinical trials in the UKIn line with our research agenda to establish trial ready thoracic surgery community in the UK with the next aim to tackle important issues in thoracic oncology (surgery versus radiotherapy trials in early and advanced disease)Critical to ensure the survival of our speciality
Slide17Meeting Room 1, Tuesday 14 March 11:30 Innovate or PerishThe Demise of Thoracic Surgery (Part III)VIOLET is funded by the National Institute for Health Research Health Technology Assessment (HTA) programme (project number 13/04/03).Department of Health Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA, NIHR, NHS or the Department of Health.